Selective COX-2 inhibition improves endothelial function in coronary artery disease

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Inflammation Research

Background:

• Ongoing debate regarding the cardiovascular safety of COX-2 inhibitors versus NSAIDs.
• Need to assess selective COX-2 inhibition effects on cardiovascular disease surrogates, especially endothelial function, in high-risk patients.

Purpose of the Study:

• To determine the impact of selective COX-2 inhibition on endothelial function and inflammatory markers in patients with coronary artery disease.

Main Methods:

• Double-blind, placebo-controlled, crossover study involving 14 male patients with severe coronary artery disease on background aspirin and statin therapy.
• Patients received celecoxib (200 mg BID) or placebo for 2 weeks.
• Assessed flow-mediated brachial artery dilation, high-sensitivity C-reactive protein, oxidized LDL, and prostaglandins.

Main Results:

• Celecoxib significantly improved endothelium-dependent vasodilation compared to placebo (3.3% vs. 2.0%, P=0.026).
• Endothelium-independent vasodilation remained unchanged.
• Celecoxib reduced high-sensitivity C-reactive protein (1.3 mg/L vs. 1.8 mg/L, P=0.019) and oxidized LDL (43.6 U/L vs. 47.6 U/L, P=0.028).

Conclusions:

• This is the first study showing selective COX-2 inhibition improves endothelial function in coronary artery disease patients.
• Selective COX-2 inhibition reduced chronic inflammation and oxidative stress.
• These findings suggest a potential beneficial impact of selective COX-2 inhibitors on cardiovascular outcomes.